As research progresses, refining these selection criteria and integrating multi-biomarker strategies will be crucial in optimizing therapeutic outcomes for SCLC patients and expanding the potential of DLL3-directed treatments. This evidence concerns the gene DLL3 and small cell lung carcinoma.